First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Gynecologic Cancer|HNSCC|Solid Tumors, Adult
Interventions: DRUG: STX-478|DRUG: Fulvestrant
Sponsor: Scorpion Therapeutics, Inc.